• Alynlam completes EU, US filings for lumasiran pharmatimes
    April 10, 2020
    Alnylam has completed the submission of marketing applications for lumasiran on both sides of the Atlantic for the ultra-rare inherited disease primary hyperoxaluria type 1 (PH1).
PharmaSources Customer Service